APB-R3

N/A

Report date: 2025/03/28 10:21:11

Base Information

Drug NameAPB-R3
Drug Alias NameLong-acting IL-18BPLong-acting interleukin-18 binding proteinEVO301EVO-301APB-R3
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionInterleukin 18 inhibitors
TargetsInterleukin 18
Therapy Area/IndicationsEczemaDermatitis, AtopicStill's Disease, Adult-Onset
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNew ZealandAustralia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAprilBio Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesEvommune IncAprilBio Co Ltd
Inactive CompaniesN/A
Active IndicationsEczemaDermatitis, AtopicStill's Disease, Adult-Onset
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A